Login to Your Account



Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad

By Catherine Shaffer
Staff Writer

Wednesday, August 22, 2012

Gilead Sciences Inc., of Foster City, Calif., has terminated a Phase II trial of cicletanine for pulmonary arterial hypertension (PAH) due to a failure of the trial to meet its primary endpoint of improvement in exercise capacity.

Gilead acquired cicletanine from Navitas Assets LLC in 2008 for a $10.9 million up-front payment and milestones. The drug is approved in some European countries for hypertension.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription